Breast Cancer Screening Test Market Report 2026

Breast Cancer Screening Test Market Overview

• Breast Cancer Screening Test market size has reached to $2.49 billion in 2025 • Expected to grow to $3.68 billion in 2030 at a compound annual growth rate (CAGR) of 8.1% • Growth Driver: Rising Breast Cancer Incidence Fueling The Growth Of The Market Due To Increasing Demand For Early Detection • Market Trend: Advancements In Mobile Diagnostic Imaging To Improve Breast Cancer Screening Accessibility • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Breast Cancer Screening Test Market?

A breast cancer screening test is a medical procedure or diagnostic tool used to detect breast cancer at an early stage, often before symptoms appear. The primary goal of screening is to identify cancer when it is most treatable, potentially reducing mortality and improving outcomes. The breast cancer screening test helps in early diagnosis, allowing for timely intervention and a better prognosis. The main diagnostic test types of breast cancer screening tests are blood marker tests, imaging tests, genetic tests, and immunohistochemistry tests. Blood marker tests detect and measure specific substances in the blood to aid in disease detection, monitoring, or risk assessment. The various risk levels include high-risk population, moderate-risk population, and average-risk population and are used by several end users, such as hospitals, diagnostic centers, cancer institutes, and research laboratories.

What Is The Breast Cancer Screening Test Market Growth Forecast?

The breast cancer screening test market size is expected to see strong growth in the next few years. It will grow to $3.68 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to rising adoption of personalized cancer screening protocols, increasing use of ai-powered diagnostic tools, expansion of genetic testing adoption, growing focus on early-stage cancer detection, increasing investments in preventive oncology services. Major trends in the forecast period include increasing adoption of advanced imaging-based screening tests, rising use of genetic and molecular diagnostics, growing integration of ai in image interpretation, expansion of multi-modal screening approaches, enhanced focus on early and preventive diagnostics.

Global Breast Cancer Screening Test Market Segmentation

1) By Diagnostic Test Type: Blood Marker Test, Imaging Test, Genetic Test, Immunohistochemistry Test 2) By Risk Level: High-risk Population, Moderate-risk Population, Average-risk Population 3) By End User: Hospitals, Diagnostic Centres, Cancer Institutes, Research Laboratories Subsegments: 1) By Blood Marker Test: Circulating Tumor Cells (Ctcs) Test, Gene Expression Profiling Test, Circulating Tumor Dna (Ctdna) Test, Proteomic Biomarker Test 2) By Imaging Test: Mammography, Magnetic Resonance Imaging Screening Test, Molecular Breast Imaging Test, Positron Emission Mammography, Ultrasound 3) By Genetic Test: Fluorescence In Situ Hybridization, Her Gene Test 4) By Immunohistochemistry (Ihc) Test: Estrogen Receptor (Er) Test, Ki-67 Proliferation Marker Test, Progesterone Receptor (Pr) Test, Her2 Or Neu Test

What Is The Driver Of The Breast Cancer Screening Test Market?

The rising breast cancer incidence is expected to propel the growth of the breast cancer screening test market going forward. Breast cancer is the uncontrolled growth of abnormal cells in the breast tissue, which can form a tumor and potentially spread to other parts of the body. The rise in breast cancer is due to the aging global population, as advancing age is a major risk factor for the disease, and longer life expectancies mean more individuals. Breast cancer screening tests help detect the disease at an early stage, increasing the chances of successful treatment and reducing breast cancer-related mortality. For instance, in March 2025, according to Breastcancer.org, a US-based nonprofit organization, around 316,950 women are expected to have a diagnosis of invasive breast cancer in 2025, while 59,080 new cases of non-invasive ductal carcinoma in situ (DCIS) are going to be reported. Therefore, the rising breast cancer incidence rates are driving the growth of the breast cancer screening test industry.

Key Players In The Global Breast Cancer Screening Test Market

Major companies operating in the breast cancer screening test market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH, Fujifilm Corporation, Koninklijke Philips NV, GE HealthCare Technologies Inc., Quest Diagnostics Incorporated, Hologic Inc., Hitachi High-Tech Corporation, Exact Sciences Corporation, Natera Inc., Myriad Genetics Inc., Canon Medical Systems Corporation, Provista Diagnostics Inc., Niramai Health Analytix Pvt. Ltd., Kheiron Medical Technologies Limited, UE LifeSciences Inc., BD (Becton Dickinson and Company), Agilent Technologies Inc.

Global Breast Cancer Screening Test Market Trends and Insights

Major companies operating in the breast cancer screening test market are focusing on developing innovative products, such as mobile cancer screening units, to enhance accessibility, improve early detection rates, and expand screening coverage in underserved and remote areas. A mobile cancer screening unit is a transportable facility with diagnostic imaging technologies, such as mammography, designed to provide on-site breast cancer screening services in remote or underserved areas. For instance, in September 2024, Granules India Ltd., an India-based pharmaceutical company, launched a Breast Health Express to boost breast cancer screening in underprivileged communities. The unit is equipped with state-of-the-art mammography and ultrasound technology, enabling high-quality screenings on the go. This initiative focuses on reaching underserved and rural communities where access to healthcare facilities may be limited, ensuring that women in remote areas have access to life-saving early detection services.

What Are Latest Mergers And Acquisitions In The Breast Cancer Screening Test Market?

In August 2024, Hitachi High-Tech Corporation, a Japan-based electronic and electrical equipment manufacturer, partnered with Gencurix Inc. for an undisclosed sum. With this partnership, Hitachi aims to leverage its expertise in in vitro diagnostics and digital technology to develop reliable and efficient cancer molecular diagnostic services. Gencurix Inc. is a South Korea-based company that provides breast cancer testing solutions.

Regional Outlook

North America was the largest region in the breast cancer screening test market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Breast Cancer Screening Test Market?

The breast cancer screening test market consists of revenues earned by entities by providing services such as early detection, risk assessment, and tumor detection. The market value includes the value of related goods sold by the service provider or included within the service offering. The breast cancer screening test market also consists of sales of products including ultrasound equipment, screening software, and breast self-examination kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.